Professor Jonathan Emberson
Jonathan Emberson
BA, MSc, PhD
Professor of Medical Statistics and Epidemiology
- MRC Population Health Research Unit Programme Leader
- MSc in Global Health Science Module Lead: Clinical Trials and Meta-Analysis
Jonathan is Professor of Medical Statistics and Epidemiology within the Nuffield Department of Population Health. After graduating in Mathematics in 1998, he studied statistics and epidemiology at MSc and PhD level before joining the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) in 2004.
His main research involves studying the causes and prevention of cardiovascular diseases through the design, conduct and analysis of large-scale observational cohort studies, randomised controlled trials, and individual-participant-data meta-analyses of both types of study. He is the UK Principal Investigator and MRC Population Health Research Unit (MRC-PHRU) Programme Leader for the Mexico City Prospective Study, a blood-based prospective cohort study of 150,000 Mexican adults followed for more than 15 years.
Recent publications
-
Diabetes and infectious disease mortality in Mexico City.
Journal article
Bragg F. et al, (2023), BMJ open diabetes research & care, 11
-
Prediction Models for Individual-Level Healthcare Costs Associated with Cardiovascular Events in the UK.
Journal article
Zhou J. et al, (2023), Pharmacoeconomics
-
Mechanisms and Predictors of Acute Kidney Injury with Perioperative Rosuvastatin in Patients Undergoing Cardiac Surgery
Preprint
Wijesurendra RS. et al, (2023)
-
Body Composition and Risk of Vascular-Metabolic Mortality Risk in 113 000 Mexican Men and Women Without Prior Chronic Disease.
Journal article
Gnatiuc Friedrichs L. et al, (2023), J Am Heart Assoc
-
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
Journal article
Nuffield Department of Population Health Renal Studies Group None. and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium None., (2022), Lancet, 400, 1788 - 1801